OncLive TV

Robert Stein, MBBS, PhD, discusses the background and design of the OPTIMA trial of test-directed chemotherapy in ER-positive, HER2-negative early breast cancer.

Marwan G. Fakih, MD, explains why obtaining a liquid biopsy at diagnosis is critical to avoid uninformative genomic results after starting chemotherapy.

Robert Stein, MBBS, PhD, discusses the data from the OPTIMA trial in ER+, HER2-negative early breast cancer and the trial's key clinical implications.

R. Lor Randall, MD, FACS, discusses how ctDNA could be used to identify microscopic residual disease in patients who appear radiographically disease-free.

Jacob Stephen Thomas, MD, discussed the efficacy of first-line ipatasertib plus pembrolizumab in patients with recurrent or metastatic HNSCC.

Marlana M. Orloff, MD, discusses efficacy and safety findings from the phase 2/3 OptimUM-02 trial in uveal melanoma.

Marwan G. Fakih, MD, discusses the clinical coordination of liquid and tissue biopsies and identifies when repeat ctDNA testing is over-utilized.

Lena Specht, MD, DMSc, discusses data for mogamulizumab in Danish patients with mycosis fungoides or Sezary syndrome and their effect on clinical practice.

Robert Stuver, MD, discusses how to approach treatment for primary cutaneous peripheral T-cell lymphoma and which factors to consider.

H. Miles Prince, MD, MBBS discusses data for mogamulizumab from MAVORIC vs real-world vorinostat in R/R MF and SS.

From CD94 antibodies to TNF-α and EZH2, Neha Mehta-Shah, MD, MSCI, explains how a wave of newly mapped targets is reshaping cutaneous T-cell lymphoma.

Neha Mehta-Shah, MD, MSCI explains how rational combinations to overcome CTCL treatment resistance keep running into added toxicity.

Julia Scarisbrick, MD, explains how better recognition of mogamulizumab-associated rash is moving the drug earlier in the mycosis fungoides and Sézary treatment course.

Julia Scarisbrick reviews real-world data showing mogamulizumab eased itch, pain, flaking, sleep, and fatigue in MF and Sézary syndrome as early as 4 weeks.

Christiane Querfeld, MD, PhD, discusses why early symptom relief drives adherence in mycosis fungoides and Sézary syndrome, and reframing MAR as an immune flare helps patients stay the course.

Christiane Querfeld, MD, PhD, discusses how targeted sequencing data show Sézary syndrome responds to mogamulizumab better than mycosis fungoides.

Jan P. Nicolay, MD, PhD, explains how early single-cell data suggest mogamulizumab resistance switches on anti-apoptotic survival proteins.

Jan P. Nicolay, MD, PhD, explains why some patients stop responding to mogamulizumab comes down to the tumor shedding its target and new survival mechanisms the cell switches on.

Two cutaneous lymphoma experts — Michael Girardi, MD, and Joan Guitart, MD — stake out opposite answers to whether SPTCL is truly a lymphoma.

Robert Stein, MBBS, PhD, discusses data from the OPTIMA trial in ER+, HER2– early breast cancer.

Alicia Morgans, MD, MPH, discusses the clinical significance of data from the phase 2 ARACOG trial in prostate cancer.

A rare cutaneous lymphoma that can mimic lupus and melt away on steroids still belongs in the malignancy category, based on how it behaves off treatment.

In part 2, the debaters map the trial that could settle the question and agree that, for now, individualized care and closer monitoring should guide high-risk early MF.

Stopping mogamulizumab after a strong response — then resuming it at relapse — emerged as a viable strategy for select patients with Sézary syndrome.

In the beginning of a two-part debate, two experts agree the evidence to treat poor-prognosis early MF differently from the onset isn’t here yet.

A planned mogamulizumab break emerged as best suited to older patients not bound for transplant, pending prospective confirmation.

Alicia Morgans, MD, MPH, discusses data on the cognitive effects of enzalutamide vs darolutamide in prostate cancer from the ARACOG trial.

Alicia Morgans, MD, MPH, discusses the background of the ARACOG trial in prostate cancer.

Sara M. Tolaney, MD, MPH, highlights the FDA approval of sacituzumab govitecan plus pembrolizumab for first-line TNBC management.

Claire Roddie, PhD, FRCPath, MBChB, MRCP, discusses outcomes with obe-cel by disease burden at screening/lymphodepletion in B-cell acute lymphoblastic leukemia.